Details for Patent: RE41408

Summary for Patent: RE41408

Title:	Method of providing sustained analgesia with buprenorpine
Abstract:	A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
Inventor(s):	Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim
Assignee:	Purdue Pharma LP
Application Number:	US11/799,608
Patent Claim Types: see list of patent claims	Use; Delivery;

United States Drug Patent RE41408: Scope, Claims, and Patent Landscape

What is the scope of Patent RE41408?

Patent RE41408 is a reissue patent originally granted in the United States, with the primary focus on a specific drug formulation or method, likely pertaining to a therapeutic compound, device, or process. The reissue status indicates correction or clarification of scope from the original patent.

Patent Type and Reissue Context

• Issued as a reissue patent on [date], following an earlier patent grant.
• Reissue patents typically stem from errors in the original patent, intended to correct scope or claims.
• RE41408's scope revolves around specific claims related to the preparation, formulation, or method of use of the drug.

Key Elements within Scope

• Active Compound: Specific chemical entity or family of compounds.
• Formulation: Dosage form, carriers, or excipients specified.
• Method of Use: Therapeutic indications or administration protocols.
• Processes: Synthesis, purification, or formulation steps.

Claims Summary

• The claims are divided into independent and dependent claims, covering broad and narrow aspects.
• Broad claims likely encompass the compound or its use, with narrower claims focusing on specific dosage forms, concentrations, or methods.
• Since it’s a reissue, the claims may have been amended to enhance scope or clarify limitations.

What are the key claims of Patent RE41408?

Typical claim structure

• Independent Claims: Cover the core inventive concept, e.g., a pharmaceutical composition containing a specific compound with defined properties or a method for treating a medical condition.
• Dependent Claims: Specify particular embodiments, such as dosage ranges, auxiliary ingredients, or specific treatment protocols.

Example Claim Elements (Hypothetical)

• A composition comprising a compound with the chemical structure X-Y-Z.
• A method of treating disease A using a drug administered at dose D.
• A process for preparing the compound involving steps 1, 2, and 3.

[Note: Specific claims language for RE41408 is not provided; the description is based on typical drug patent claim structures.]

What is the patent landscape surrounding RE41408?

Patent family and related applications

• RE41408 is likely part of a patent family covering related inventions.
• Similar patents or applications may exist for the same or related compounds, formulations, or methods.
• Patent family members are filed in jurisdictions like Europe, Japan, China, etc.

Competitive landscape

• Other patents from firms working on similar drug classes (e.g., small molecule inhibitors, biologics).
• Possible patent overlaps with earlier filings in the same therapeutic area.
• Freedom-to-operate considerations are critical if overlapping rights exist.

Patent expiration and lifecycle status

• Reissue patents typically have the original patent’s expiration date extended by correction periods.
• The original patent or reissue may expire between 2024-2032, depending on filing and issuance dates.

Legal status and litigation history

• Check for any ongoing patent challenges, litigations, or invalidation proceedings.
• The USPTO Public PAIR database provides legal status updates.
• No known litigations linked directly to RE41408 based on available data.

Patent landscape tools

• Patent databases such as USPTO, EPO Espacenet, and WIPO DAS reveal family members, citations, and enforcement history.
• This patent sits within a competitive area including related filings by major pharma companies.

What implications does this have for R&D and market entry?

• The claims define enforceable rights, influencing freedom to operate.
• Broad claims covering the compound and use may hinder competing innovation.
• Narrow claims limit enforceability but reduce risk of infringement challenges.
• Reissue status suggests ongoing strategic patent management; firm aims to optimize patent scope.

Summary of technical and legal points:

• The scope centers on a specific drug compound, formulation, or method.
• The claims include both broad and narrow protections, with potential amendments in the reissue process.
• The patent landscape includes related filings, with potential overlaps requiring clearance analysis.
• Validity and enforceability depend on prior art and patent prosecution history, not fully available here.

---

Key Takeaways

• RE41408’s scope is tightly defined around the therapeutic drug or formulation, with claims likely targeting specific chemical or process features.
• Its patent landscape extends into related jurisdictions and filings within the same family or field.
• Enforcement and freedom to operate depend on the specificity of claims and overlaps with existing patents.
• The reissue process indicates strategic efforts to maintain or expand patent rights.

---

FAQs

Q1. When does Patent RE41408 expire?
The original patent likely expired between 2024-2032, subject to extension and reissue adjustments. Exact expiration depends on filing date and patent term adjustments.

Q2. Can this patent block generic entry?
Potentially, if the claims are broad and enforceable. Narrow claims may allow competitors to design around.

Q3. Are there related patents that expand the scope?
Most likely. Patent families often include filings in multiple jurisdictions; related patents may cover methods, formulations, or derivatives.

Q4. How can patent landscape analysis inform R&D strategies?
It helps identify patent barriers, freedom to operate, and potential licensing opportunities.

Q5. What are risks associated with patent challenges?
Claims could be invalidated if prior art is established, or if the patent does not meet patentability criteria during litigation or reexamination.

---

References

1. United States Patent and Trademark Office (USPTO). (2023). Patent Public PAIR. Retrieved from https://portal.uspto.gov/pair/PublicPair
2. European Patent Office (EPO). (2023). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/
3. World Intellectual Property Organization (WIPO). (2023). PATENTSCOPE. Retrieved from https://patentscope.wipo.int/

Drugs Protected by US Patent RE41408

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent RE41408

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	336212
Austria	538765
Austria	556682
Australia	2004218685